Grant: Alliance Grants
University of Windsor
$30,000.00
Adaptation of TeamBest FDG Technology Applied to Novel Prostate Cancer Specific Tracers _x000d_ _x000d_
FY 2020-21
Summary
The usefulness of positron emission tomography (PET) imaging is best demonstrated by current data suggesting that in as many as one-third to one-half of cancer cases, physicians who do not have access to PET may be choosing the wrong management or treatment strategy for their patients.
PET imaging relies on radiopharmaceuticals label with a radioactive element that decays through positron emmission. By far the most common radioisotope used for PET imagine is fluorine-18. The isotope fluorine-18 decays rapidly, with a half-life of 110 minutes. Such a short half-life makes shipping the radiotracers long distances expensive and often impractical. Thus synthesis of the radiopharmaceutical is ideally performed at the source of of fluorine 18.
Although 96% of PET scans are perfomed with fluorodeoxyglucose (FDG), this particular radiotracer is non-specific and not ideal when monitior specific types of cancers. A up-and-coming PET approach is the use of Prostate specific membrane antigen imaging (PSMA). PSMA PET is very sensitive for detecting prostate cancer and is currently used in patients with new diagnosis of high-risk prostate cancer and those with biochemical recurrence. Thus, a reliable and expedient synthesis method of PSMA related PET agents is of high interest to the medical industry.
Program
Alliance Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
560741-2020
Name nom
Marquardt, Drew
Department département
Chemistry and Biochemistry
Organization id
37
Institution établissement
University of Windsor
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
30000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Adaptation of TeamBest FDG Technology Applied to Novel Prostate Cancer Specific Tracers _x000d_
_x000d_
Keyword
NSERC
Application summary
The usefulness of positron emission tomography (PET) imaging is best demonstrated by current data suggesting that in as many as one-third to one-half of cancer cases, physicians who do not have access to PET may be choosing the wrong management or treatment strategy for their patients.
PET imaging relies on radiopharmaceuticals label with a radioactive element that decays through positron emmission. By far the most common radioisotope used for PET imagine is fluorine-18. The isotope fluorine-18 decays rapidly, with a half-life of 110 minutes. Such a short half-life makes shipping the radiotracers long distances expensive and often impractical. Thus synthesis of the radiopharmaceutical is ideally performed at the source of of fluorine 18.
Although 96% of PET scans are perfomed with fluorodeoxyglucose (FDG), this particular radiotracer is non-specific and not ideal when monitior specific types of cancers. A up-and-coming PET approach is the use of Prostate specific membrane antigen imaging (PSMA). PSMA PET is very sensitive for detecting prostate cancer and is currently used in patients with new diagnosis of high-risk prostate cancer and those with biochemical recurrence. Thus, a reliable and expedient synthesis method of PSMA related PET agents is of high interest to the medical industry.